Aim: The PLANET trials showed that atorvastatin 80 mg but not rosuvastatin at either 10 or 40 mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL-cholesterol. However, individual changes in both UPCR and LDLcholesterol during treatment with these statins varied widely between patients. This inter-individual variability could not be explained by patients' physical or biochemical characteristics. We assessed whether the plasma concentrations of both statins were associated with LDL-cholesterol and UPCR response. Materials and methods: The PLANET trials randomized patients with a UPCR of 500-5000 mg/g and fasting LDL-cholesterol >2.33 mmol/L to a 52-week treatment with atorvastatin 80 mg, rosuvastatin 10 mg or 40 mg. For the current analysis, patients with available samples at week 52 and treatment compliance >80% by pill count were included (N = 295). The main outcome measurements were percentage change in UPCR and absolute change in LDL-cholesterol (delta LDL) from baseline to week 52.
| INTRODUCTION
Lipid-lowering therapy is part of the guideline recommended treatment for cardiovascular protection in patients with diabetes and chronic kidney disease. 1 The effects of statins on kidney function remain unclear. Some studies show a renoprotective profile of a particular statin whereas other studies have suggested that some statins may exert harmful effects. [2] [3] [4] [5] [6] The PLANET trials were designed to assess the effects of atorvastatin and rosuvastatin on proteinuria and estimated glomerular filtration rate (eGFR). The trials showed that not all statins are similar in their effects on renal variables even at equipotent lipid-lowering effects. 7 PLANET showed that atorvastatin but not rosuvastatin decreased mean proteinuria, while mean eGFR decline was less with atorvastatin than with rosuvastatin despite similar cholesterol-lowering efficacy. 7 A post hoc analysis of these trials showed a large variation in individual patient responses in proteinuria and lipid variables for both statins, which could not be explained by clinical patient characteristics. 8 Drug concentrations of these statins or their active metabolites have been shown to play a role in the variation of lipid-lowering effects. 9, 10 Such data are not available for the proteinuria response to these statins.
To provide more insight into the underlying mechanisms of the individual variation in response to statins, we investigated whether drug plasma concentration of atorvastatin, rosuvastatin or their metabolites were a determinant of the individual albuminuria and LDL-cholesterol response. We also assessed which patient characteristics were associated with the variation in drug concentration.
| MATERIALS AND METHODS

| Study design and protocol
Combined data from the PLANET I and PLANET II trials were used for this analysis. The design and primary results of both trials were reported previously. 7 In short, the PLANET trials were randomized, double-blind, 52-week, parallel-group, multicentre, phase 3 studies.
Eligible patients were randomly assigned to treatment with atorvastatin 80 mg/day, rosuvastatin 10 mg/day or rosuvastatin 40 mg/day for 52 weeks after an 8-week lead-in period in which dietary advice was given, existing hypertensive treatment was optimized and statins were discontinued if applicable. The study protocols of the PLANET trials are registered with clinicaltrials.gov (PLANET I: NCT00296374
and PLANET II: NCT00296400). The trials were performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by independent ethics committee. All participants signed written informed consent before the start of any study-specific procedure. were not included for the following reasons: 178 had no plasma sample available at week 52, 44 did not adhere to therapy (<80% compliance by pill count) and 25 subjects were excluded for other reasons.
| Patients
| Measurements
Height was collected once at the start of the screening. Vital signs including blood pressure, weight and pulse rate, urine samples (collected at three consecutive morning voids before the study visit) and biochemistry, including but not limited to albumin, bilirubin, creatinine, 
| RESULTS
Clinical and biochemical characteristics as well as statin plasma concentrations are presented in Table 1 . The mean eGFR was 76 mL/min/1.73m 2 for all three dose groups, median UPCR ranged between 1074 and 1315 mg/g and mean LDL-cholesterol ranged between 1.8 and 2.4 mmol/L for the three dose groups. Figure 3 ). The metabolites of both statins tended to correlate with LDL-cholesterol change (Table S1 ). None of the metabolites correlated with UPCR or UACR change.
Finally, we assessed which patient characteristics were associated with the variation in plasma concentrations of the statins. None of the assessed patient characteristics were associated with variation in atorvastatin plasma concentration (Table 3 ). For rosuvastatin, lower eGFR T A B L E 2 Pearson correlations between plasma concentrations of atorvastatin and rosuvastatin and delta LDL-cholesterol (mmol/l) and log delta urinary protein to creatinine ratio (UPCR) and urinary albumin to creatinine ratio (UACR) at week 52 and higher serum albumin were independently associated with higher plasma concentration (Table 3 ).
| DISCUSSION
In this study we tested whether the large individual variation in lipid lowering as well as proteinuria lowering response to two different statins (atorvastatin and rosuvastatin) was associated with the achieved individual plasma statin levels in proteinuric patients with or without diabetes. We found that variations in plasma levels of the statins were associated with the variation in LDL-cholesterol-lowering effect. The large variation in proteinuria lowering was not associated with variations in plasma drug levels of either atorvastatin or rosuvastatin.
The large between-individual variation in plasma concentrations of atorvastatin and rosuvastatin is consistent with findings from other statin trials. 9, 12, 13 We found a marked overlap in plasma concentrations among patients assigned to rosuvastatin 10 mg and 40 mg, indicating that the individual exposure of a patient at low dose rosuvastatin can exceed the exposure of an individual treated with a four times higher dose. These data suggest that individual characteristics determine the plasma level of a statin. We found that a lower eGFR was associated with a higher rosuvastatin plasma concentration. Although hepatic clearance is the major route of rosuvastatin clearance, rosuvastatin is in part also excreted by the kidneys and the lower eGFR level may reflect diminished renal clearance. High serum albumin was also associated with higher plasma concentration. We speculate that because of the high protein binding of rosuvastatin, the free fraction decreases when serum albumin increases. As bound rosuvastatin cannot readily leave the capillaries, total plasma rosuvastatin may increase. As rosuvastatin is subject to both hepatic and, more importantly, renal elimination, the potentially lower fraction of unbound drug can also reduce the clearance leading to a higher total plasma concentration of rosuvastatin over time. Little is known from the literature about the association between plasma concentration and LDL response at an individual patient level.
Multiple dose finding studies with both atorvastatin and rosuvastatin have reported strong dose-dependent effects of statins on LDL-cholesterol. 14, 15 Specifically, pharmacokinetic studies with rosuvastatin showed an approximately linear relationship between dose and area under the rosuvastatin concentration time curve for doses ranging from 5 to 80 mg. 16, 17 However, these studies assessed the dose exposure relationship at a population level but not the exposure response at an individual patient level. We found that lower plasma concentrations of the statins were associated with a lower LDL-cholesterol response at an individual patient level. Given that higher doses are associated with higher plasma concentrations, this finding indicates that to enhance the LDL-cholesterol-lowering effect a higher dose is probably required.
There are to our knowledge no data in the literature regarding a dose-response or exposure-response relationship of a statin on proteinuria lowering (or increase). We found that both statins had clearly varying effects on proteinuria and albuminuria: atorvastatin lowers both proteinuria and albuminuria whereas rosuvastatin does not, both measured at a population level. However, at an individual level, both statins
show a wide range of responses varying from distinct proteinuria lowering to increases. 8 The potential mechanisms mediating albuminuria-lowering effects are unclear although various hypotheses have been postulated.
Among other things, it has been suggested that statins may protect podocytes, reduce endothelial dysfunction, or reduce tubulointerstitial injury. 18 We did not observe a correlation between the individual plasma concentration of both statins and proteinuria or albuminuria. The lack of correlation indicates that the systemic exposure is not a reflection of the individual response. It is possible that intra-renal exposure is a better indicator of the individual proteinuria response.
Nevertheless, we cannot exclude the possibility that random variations in proteinuria obscure a true association, although the large sample size in this study provided sufficient power to detect even modest correlations.
T A B L E 3 Patient characteristics associated with plasma concentrations of atorvastatin 80 mg and rosuvastatin 10 and 40 mg at week 52 
